studies

984A AASLD ABSTRACTS HEPATOLOGY, October, 2015
was lower in patients with F4-F6 (n=27) compared to those
with F0-F3 (7.6 vs. 8.1 log U/mL, p=0.02), and declined with
increasing fibrosis stage (Figure). HBcrAg levels were independently
associated with advanced fibrosis when adjusting
for age and serum ALT (OR 0.5, CI-95% 0.3-0.8, p=0.003).
In HBeAg-negative patients, fibrosis stage was available for
all patients. The mean HBcrAg was 5.5 (SD 0.1), median HAI
score 5 (IQR 3), and median Ishak fibrosis stage 3 (IQR 2).
Genotypes A/B/C/D/other were present in 13/1/2/81/3%.
In these patients, log HBcrAg was not correlated with Ishak
fibrosis score (r s
=-0.1, p=0.59), similar to fibrosis correlation
to qHBsAg (r s
=-0.1, p=0.19), and HBV DNA (r s
=0.2, 0.07).
When adjusting for age and serum ALT, HBcrAg levels were
not associated with advanced fibrosis (OR 0.9, CI-95% 0.5-
1.6, p=0.83) and did not change with increasing fibrosis
stage (Figure). For both HBeAg-positive and HBeAg-negative
patients, variation of qHBsAg levels across fibrosis stages
was comparable to that of HBcrAg levels (Figure). Conclusion.
In this study, serum HBcrAg levels were inversely correlated
with Ishak fibrosis stage in HBeAg-positive CHB, but not in
HBeAg-negative CHB.
obtainable mutation analysis in 2 centers. Of 177 HBeAg(+)
patients, 6(3.39%) were genotype A, 65(36.72%) genotype
B, 104(58.76%) genotype C, 1(0.57%) genotype B/C, and
1(0.57%) genotype C/D. Of 90 HBeAg(-) patients, 1(1.11%)
were genotype A, 50(55.56%) genotype B, 37(41.11%) genotype
C and 2(2.22%) genotype D. When compared to HBeAg(-)
patients, HBeAg(+) patients were significantly younger in mean
age (37.93 vs. 44.40; P